Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDDP for Post-MI Ventricular Remodeling
NCT05000411Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Compound Danshen in myocardial infarction (MI) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Left Ventricle Ejection Fraction at 24 weeks, Left Ventricular End-Diastolic Volume Index at 24 weeks and 1 more. Status: unknown.
02
Drugs
Compound Danshen
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05000411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000411.